Search

Displaying results 811 - 820 of 2955 in total
  1. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

  2. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the

  3. Drug

    Candesartan

    go.drugbank.com/drugs/DB13919
    Investigational

    Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

    Mixtures: CANDESARTAN E IDROCLOROTIAZIDE EG, CANDESARTAN E IDROCLOROTIAZIDE EGProducts: CANDESARTAN EG, CANDESARTAN E IDROCLOROTIAZIDE ZENTIVA
  4. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]

    Synonyms: Clobetasol propionate EInternational brands: Embeline E
  5. Drug

    Caviar, unspecified

    go.drugbank.com/drugs/DB14241
    Approved

    Caviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Elm

    go.drugbank.com/drugs/DB14258
    Approved

    Elm is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  7. Drug

    Wormwood

    go.drugbank.com/drugs/DB14291
    Approved

    Wormwood is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  8. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617] … [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking

  9. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.

  10. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist … Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).